Royalty Pharma (RPRX) Change in Cash (2019 - 2026)

Royalty Pharma has disclosed Change in Cash across 8 years of filings, most recently posting $225.6 million for Q2 2026.

• In Q2 2026, Change in Cash rose 149.49% year-over-year to $225.6 million; the TTM figure through Jun 2026 stood at $180.1 million (up 115.9% YoY), while the FY2025 annual figure was -$310.3 million, down 168.65% from the prior year.
• Change in Cash came in at $225.6 million for Q2 2026 at Royalty Pharma, up from -$32.3 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $921.6 million in Q2 2024 to a low of -$1.2 billion in Q3 2023.
• Average Change in Cash over 5 years is -$40.5 million, with a median of $178.0 million recorded in 2023.
• Year-over-year, Change in Cash jumped 376.84% in 2022 and tumbled 1423.1% in 2025.
• Over 5 years, Change in Cash stood at $719.1 million in 2022, then tumbled by 163.89% to -$459.4 million in 2023, then soared by 95.42% to -$21.0 million in 2024, then plunged by 1423.1% to -$320.2 million in 2025, then jumped by 170.44% to $225.6 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were $225.6 million in Q2 2026, -$32.3 million in Q1 2026, and -$320.2 million in Q4 2025.